HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over-expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined wi
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
โ Scribed by Hirsch, F R; Varella-Garcia, M; Franklin, W A; Veve, R; Chen, L; Helfrich, B; Zeng, C; Baron, A; Bunn, P A
- Book ID
- 109997244
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 529 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Evidence for the existence of neuroendocrine (NE) differentiation in non-small cell lung carcinomas (NSCLCs) is at present based on histochemical, ultrastructural, and immunohistochemical data. The aim of this study was to investigate the extent of NE differentiation in NSCLCs as revealed by mRNA an
MRP has been identified as another multidrug-resistance (MDR) gene and may be involved in an alternative MDR mechanism in some solid tumors. We investigated the expres- sion of M R P mRNA in multidrug-resistant KB sublines (KB-8-5, KB-CZ, C -W and C A I to), human non-small-cell lung carcinomas (NSC